We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.50 | -0.72% | 342.50 | 335.00 | 350.00 | 345.00 | 342.50 | 345.00 | 24,274 | 16:17:54 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 44.26M | -23.57M | -0.2277 | -18.40 | 433.68M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/3/2017 10:41 | Maxcyte CEO Doug Doerfler will be presenting to investors at the upcoming Proactive One2One Forum taking place on the evening of 23rd March in Mayfair, London. For details and registration, please click here: | aim_trader | |
14/3/2017 18:18 | I thought they might go a bit higher today on the back of that news, so I'll save the the next rocket for a better day, meanwhile there's a new interview with Doug Doerfler on Proactive investor which is well worth a listen: in response to a question on why do they (i.e. big biotech) come to MaxCyte? DD states in his response: .......we can deliver any molecule to any cell at any scale and we do it highly efficiently, high performance and we also do it in a clinical setting so it can be used to modify those cells to engineer cells and return those cells to the patient and we are the only group who can do that clinically......" Which goes some way to explain why the shares are in such demand | timbo003 | |
14/3/2017 08:41 | Time for another Rocket video clip Tim? | davep4 | |
14/3/2017 08:23 | New Trinity Delta Research note now out following today's announcement: | timbo003 | |
10/3/2017 22:53 | MaxCyte will be presenting at the Proactive investor evening on Thursday March 23rd, I plan to attend and will report back in due course: | timbo003 | |
13/2/2017 10:14 | Mornin' ali I find it impossible to value this one, I bought primarily for the tax breaks as you know. I dont really believe in reading tea leaves, but I suspect the chartists would have said it was overdue a big correction at 280p, mind you they would probably have told you the same thing at 140p and 210p on the way up (and it didnt happen). This is one share where I havent been able to talk to the ,management, so all I have to go on is what is in the public domain. The Trinity Development research notes are a useful read if you haven't already seen them | timbo003 | |
12/2/2017 12:13 | hi timbo you probably have studied this one thoroughly- i have been watching it and i notice it is down 30pc- but no clue as to whether this presents an opportunity to enter? just interested in your take! | ali47fish | |
07/2/2017 14:25 | Let sleeping dogs lie timbo003! | davep4 | |
06/2/2017 17:40 | This is now a 4 bagger since the IPO, or a 5.5 bagger if you take into account the EIS tax relief. I find it quite extraordinary that there is no interest here. I would have thought at least the Scancell crowd might have had a sniff around, given that MaxCyte's business is all about Electroporation and Scancell's lead drug (SCIB1) requires electroporation for effective delivery. | timbo003 | |
27/1/2017 16:35 | Here's a date for your diaries 23rd March MaxCyte will be presenting at the Proactiveinvestor evening at the Chesterfield Hotel in Mayfair, It's free and you get fed and watered afterwards, so I've booked my place. | timbo003 | |
26/1/2017 17:29 | Another good day, market cap now just a tad over £100m, presumably it will now get on a few more radar screens. | timbo003 | |
25/1/2017 08:02 | Thanks for that dave4p, there is also a new note available from Trinity Delta here: | timbo003 | |
12/1/2017 08:21 | The publication referred to in today's RNS appears to concern the work referred to in Panmure Gordon's morning note from last week. Up again today, now 3X the IPO price, or over 4X the price paid by IPO participants who qualified for EIS tax reliefs (i.e. 49p/share). | timbo003 | |
11/1/2017 09:02 | Yes and from memory 50+ licencees,(up from 30+ at the time of the float). | davep4 | |
11/1/2017 08:38 | Thanks Dave4p That note from Panmure puts the rise into context, so they are now looking at a new platform which is likely to be of considerable interest to big pharma and it sounds like Maxcyte are the only shop in town | timbo003 | |
10/1/2017 14:10 | And the following update by PG: | davep4 | |
06/1/2017 19:59 | Thanks leedskier Found it: | timbo003 | |
06/1/2017 15:25 | The Ft has named it as the top pharma small cap stock pick of 2017. | leedskier | |
06/1/2017 10:06 | Up today again and I am still none the wiser There is nothing obvious on their twitter feed, other than they will be presenting at Biotech show case next week which surely wouldn't account for this rise | timbo003 | |
05/1/2017 11:26 | Time for another animated gif! I have no idea why these are up today, or why no one else in the ADVFN and LSE cyber communities have shown any interest in this one, but I am quite happy to be a Norman no mates if the performance continues like this | timbo003 | |
22/12/2016 05:41 | New video of CEO Doug Doerfler discussing the latest announcement regarding MaxCytes's CARMA platform: | timbo003 | |
29/11/2016 09:56 | don't worry timbo it will soon drift back down again | jinky2 | |
29/11/2016 08:56 | Drifting up for no easily discernable reason, normally my AIM shares do the opposite in the absence on news. If only they were all like this one (sigh!) | timbo003 | |
28/10/2016 07:35 | >>davep4, indeed. I wish I had as much in this one as have in Cyan. I seem to have an exceptional talent for underinvesting in shares which take off like this one! | timbo003 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions